Leading International Investment Research, Edison Investment Research

Edison Investment Research

Leading International Investment Research

Edison is an investment research and advisory company, with offices in North America, Europe, the Middle East and AsiaPac. The heart of Edison is our world renowned equity research platform and deep multi-sector expertise. At Edison Investment Research, our research is widely read by international investors, advisors and stakeholders. Edison Advisors leverages our core research platform to provide differentiated services including investor relations and strategic consulting.

Equity Bottom-Up

Cannabics develops cannabinoid-based, tumour reducing therapies. Its bioinformatics platform evaluates the efficacy of thousands of cannabinoid compounds on various cancers. In addition, it has recently launched a psychedelic inspired research programme focused on neuropsychiatric disorders. Its most advanced therapies target the $18bn colorectal cancer market, with human clinical trials planned to commence in 2022. Earlier-stage therapies target breast cancer, prostate cancer and melanomas. Cannabics has five granted patents and 20 patents pending.

Cannabics develops cannabinoid-based, tumour reducing therapies. Its bioinformatics platform evaluates the efficacy of thousands of cannabinoid compounds on various cancers. In addition, it has recently launched a psychedelic inspired research programme focused on neuropsychiatric disorders. Its most advanced therapies target the $18bn colorectal cancer market, with human clinical trials planned to commence in 2022. Earlier-stage therapies target breast cancer, prostate cancer and melanomas. Cannabics has five granted patents and 20 patents pending.

Cannabics Pharmaceuticals - Developing cannabinoid-based therapies

Transport Sector, China and Asia-focused Research

Charles De Trenck

We are at the start of a new page for an old industry, with marijuana becoming legal in many markets faster than we could have imagined a decade ago. The move this week by<a href="https://www.smartkarma.com/entities/8065" target="_blank" data-smartkarma-citation="entities:8065:1">Constellation Brands Inc A (STZ US)</a> to increase its stake in <a href="https://www.smartkarma.com/entities/25083" target="_blank" data-smartkarma-citation="entities:25083:1">Canopy Growth (WEED CN)</a> is a game changer.Some US states have made the move into medical and recreational marijuana, with California becoming the big catch in Jan 2018. We all know this, and this has been reflected in share prices of many counters in 2017-18 rallies.…

We are at the start of a new page for an old industry, with marijuana becoming legal in many markets faster than we could have imagined a decade ago. The move this week byConstellation Brands Inc A (STZ US) to increase its stake in Canopy Growth (WEED CN) is a game changer.Some US states have made the move into medical and recreational marijuana, with California becoming the big catch in Jan 2018. We all know this, and this has been reflected in share prices of many counters in 2017-18 rallies.…

Cannabis: Game Change Buy In from Alcoholic Beverages Player (Constellation Brands + Canopy Growth)

United States

CNBX Pharmaceuticals Inc. operates as a pharmaceutical company. The Company develops cannabinoid-based antitumor drug candidate for the treatment of colorectal cancer based on novel and proprietary formulation. CNBX Pharmaceuticals serves patients in the United States.

Price Gauge
52-week Range	0.00 - 0.00
Market Cap (USDm)	0.00
P/E	0.00
Dividend (Yield)	0.00

CNBX Pharmaceuticals (CNBX US)

Cannabics Pharmaceuticals - Developing cannabinoid-based therapies

Cannabics develops cannabinoid-based, tumour reducing therapies. Its bioinformatics platform evaluates the efficacy of thousands of cannabinoid...

Edison Investment Research

Cannabis: Game Change Buy In from Alcoholic Beverages Player (Constellation Brands + Canopy Growth)

We are at the start of a new page for an old industry, with marijuana becoming legal in many markets faster than we could have imagined a decade...

Charles De Trenck

Price Gauge

52-week Range

Market Cap (USDm)

P/E

Dividend (Yield)